|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4675187A
(en)
|
1983-05-16 |
1987-06-23 |
Bristol-Myers Company |
BBM-1675, a new antibiotic complex
|
|
US4663281A
(en)
|
1984-03-22 |
1987-05-05 |
Mass Institute Of Technology |
Enhanced production of proteinaceous materials in eucaryotic cells
|
|
US4789633A
(en)
|
1984-04-19 |
1988-12-06 |
University Of Tennessee Research Corporation |
Fused liposome and acid induced method for liposome fusion
|
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE68927933T2
(de)
|
1988-09-02 |
1997-08-14 |
Dyax Corp |
Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
JP3051162B2
(ja)
|
1989-09-20 |
2000-06-12 |
アボット ラボラトリーズ |
融合蛋白質の製造方法
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5780225A
(en)
|
1990-01-12 |
1998-07-14 |
Stratagene |
Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
|
|
WO1991010737A1
(en)
|
1990-01-11 |
1991-07-25 |
Molecular Affinities Corporation |
Production of antibodies using gene libraries
|
|
DE69133566T2
(de)
|
1990-01-12 |
2007-12-06 |
Amgen Fremont Inc. |
Bildung von xenogenen Antikörpern
|
|
US5314995A
(en)
|
1990-01-22 |
1994-05-24 |
Oncogen |
Therapeutic interleukin-2-antibody based fusion proteins
|
|
CA2077348A1
(en)
|
1990-03-02 |
1991-09-03 |
Stephen D. Gillies |
Antibody constructs with enhanced binding affinity
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
WO1992002551A1
(en)
|
1990-08-02 |
1992-02-20 |
B.R. Centre Limited |
Methods for the production of proteins with a desired function
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5698426A
(en)
|
1990-09-28 |
1997-12-16 |
Ixsys, Incorporated |
Surface expression libraries of heteromeric receptors
|
|
GB9021679D0
(en)
|
1990-10-05 |
1990-11-21 |
Gorman Scott David |
Antibody preparation
|
|
DE69133036T2
(de)
|
1990-11-09 |
2003-02-06 |
Stephen D. Gillies |
Cytokine immunokonjugate
|
|
WO1992008801A1
(en)
|
1990-11-09 |
1992-05-29 |
Abbott Laboratories |
Bridging antibody fusion constructs
|
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
|
DK1471142T3
(da)
|
1991-04-10 |
2009-03-09 |
Scripps Research Inst |
Heterodimere receptor-biblioteker under anvendelse af fagemider
|
|
AU666852B2
(en)
|
1991-05-01 |
1996-02-29 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
A method for treating infectious respiratory diseases
|
|
GB9112536D0
(en)
|
1991-06-11 |
1991-07-31 |
Celltech Ltd |
Chemical compounds
|
|
DE69233745D1
(de)
|
1991-12-02 |
2008-10-23 |
Cambridge Antibody Tech |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
US5874082A
(en)
|
1992-07-09 |
1999-02-23 |
Chiron Corporation |
Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
|
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
|
JP3734262B2
(ja)
|
1993-03-25 |
2006-01-11 |
メルク エンド カンパニー インコーポレーテッド |
血管内皮細胞増殖因子阻害剤
|
|
JP3675819B2
(ja)
|
1993-10-01 |
2005-07-27 |
イミュネックス・コーポレーション |
Ｃｄ４０に対する抗体
|
|
JPH09506262A
(ja)
|
1993-12-08 |
1997-06-24 |
ジェンザイム・コーポレイション |
特異的抗体の製造方法
|
|
DE69433820T2
(de)
|
1993-12-23 |
2005-06-23 |
Immunex Corp., Seattle |
Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
|
|
IL108501A
(en)
|
1994-01-31 |
1998-10-30 |
Mor Research Applic Ltd |
Antibodies and pharmaceutical compositions containing them
|
|
DE69534347T2
(de)
|
1994-01-31 |
2006-05-24 |
Trustees Of Boston University, Boston |
Bibliotheken aus Polyklonalen Antikörpern
|
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
|
KR100257466B1
(ko)
|
1994-05-06 |
2000-07-01 |
레지날드 쇼트버그 에스. 안토니우스-소도 |
Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법 치료 조성물, 항-이디오타입 항체
|
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
|
US5516637A
(en)
|
1994-06-10 |
1996-05-14 |
Dade International Inc. |
Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
AU5265296A
(en)
|
1995-04-10 |
1996-10-30 |
Universite De Sherbrooke |
Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6576754B2
(en)
|
1995-11-09 |
2003-06-10 |
Dana-Farber Cancer Institute |
CD100 antigen and uses therefor
|
|
JP2978435B2
(ja)
|
1996-01-24 |
1999-11-15 |
チッソ株式会社 |
アクリロキシプロピルシランの製造方法
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
JP2000506165A
(ja)
|
1996-03-04 |
2000-05-23 |
ザ ペン ステイト リサーチ ファウンデーション |
細胞インターナリゼーションを増強するための物質および方法
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
|
JP2000512482A
(ja)
|
1996-06-17 |
2000-09-26 |
マックス―プランク―ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
新規ｐｔｐ２０、ｐｃｐ―２、ｂｄｐ―１、ｃｌｋ、およびｓｉｒｐタンパク質並びに関連する生成物および方法
|
|
AU3505397A
(en)
|
1996-06-25 |
1998-01-14 |
Trustees Of The University Of Pennsylvania, The |
Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
|
|
ATE374248T1
(de)
|
1996-06-27 |
2007-10-15 |
Vlaams Interuniv Inst Biotech |
Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
|
|
NL1003648C2
(nl)
|
1996-07-19 |
1998-01-21 |
Carino Cornelis Sunderman |
Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
|
|
US6028176A
(en)
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
|
AU738806B2
(en)
|
1996-09-24 |
2001-09-27 |
Merck & Co., Inc. |
Gene therapy for inhibition of angiogenesis
|
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
PT954282E
(pt)
|
1997-01-16 |
2005-06-30 |
Massachusetts Inst Technology |
Preparacao de particulas para inalacao
|
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
|
US20070015696A1
(en)
|
1997-03-07 |
2007-01-18 |
Rosen Craig A |
621 human secreted proteins
|
|
US20070055056A1
(en)
|
1997-03-07 |
2007-03-08 |
Rosen Craig A |
251 human secreted proteins
|
|
US20080103090A1
(en)
|
1997-03-07 |
2008-05-01 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US20060223090A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Polynucleotides encoding human secreted proteins
|
|
US7968689B2
(en)
|
1997-03-07 |
2011-06-28 |
Human Genome Sciences, Inc. |
Antibodies to HSDEK49 polypeptides
|
|
US20060246483A1
(en)
|
1997-03-07 |
2006-11-02 |
Rosen Craig A |
337 human secreted proteins
|
|
US7411051B2
(en)
|
1997-03-07 |
2008-08-12 |
Human Genome Sciences, Inc. |
Antibodies to HDPPA04 polypeptide
|
|
US20060223088A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Human secreted proteins
|
|
US7368531B2
(en)
|
1997-03-07 |
2008-05-06 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
|
BR9810620A
(pt)
|
1997-06-20 |
2000-10-03 |
Biogen Inc |
Terapia de bloqueio de cd154 para transplante de tecido da ilhota pancreática
|
|
US6075007A
(en)
|
1997-07-17 |
2000-06-13 |
Regeneron Pharmaceuticals, Inc. |
Modified noggin polypeptide and compositions
|
|
AR013184A1
(es)
|
1997-07-18 |
2000-12-13 |
Astrazeneca Ab |
Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
|
|
DE19821060A1
(de)
|
1997-09-23 |
1999-04-15 |
Bundesrepublik Deutschland Let |
Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
|
|
WO1999015553A2
(de)
|
1997-09-23 |
1999-04-01 |
Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts |
Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
|
|
EP1032662B1
(en)
|
1997-11-07 |
2006-03-08 |
Trillium Therapeutics Inc. |
Methods and compositions for immunomodulation
|
|
JP4336452B2
(ja)
|
1997-12-08 |
2009-09-30 |
メルク パテント ゲーエムベーハー |
標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質
|
|
US6051228A
(en)
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
|
BR9908226A
(pt)
|
1998-02-25 |
2000-10-24 |
Lexigen Pharm Corp |
Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
|
|
US6979547B2
(en)
|
1998-03-25 |
2005-12-27 |
Cornell Research Foundation, Inc. |
Methods for designing specific ion channel blockers
|
|
WO1999050461A1
(en)
|
1998-03-30 |
1999-10-07 |
Northwest Biotherapeutics, Inc. |
Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
|
|
MXPA00010070A
(es)
|
1998-04-15 |
2004-03-10 |
Lexigen Pharm Corp |
Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
|
|
BR9909677A
(pt)
|
1998-04-17 |
2000-12-19 |
Lexigen Pharm Corp |
Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas
|
|
GB9809839D0
(en)
|
1998-05-09 |
1998-07-08 |
Glaxo Group Ltd |
Antibody
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
WO1999061057A2
(en)
|
1998-05-23 |
1999-12-02 |
Tanox, Inc. |
Molecules targeting cd40 and tumor cells
|
|
WO1999066903A2
(en)
|
1998-06-24 |
1999-12-29 |
Advanced Inhalation Research, Inc. |
Large porous particles emitted from an inhaler
|
|
EP1133563A2
(en)
|
1998-07-16 |
2001-09-19 |
Hyseq, Inc. |
Methods and molecules relating to cd39-like polypeptides
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
US6696550B2
(en)
|
1998-07-23 |
2004-02-24 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
|
WO2000011033A2
(en)
|
1998-08-25 |
2000-03-02 |
Lexigen Pharmaceuticals Corp. |
Expression and export of angiostatin and endostatin as immunofusins
|
|
AU1224200A
(en)
|
1998-10-23 |
2000-05-15 |
Agnes Vignery |
Methods for modulating cell fusion
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
WO2000040615A2
(en)
|
1999-01-07 |
2000-07-13 |
Lexigen Pharmaceuticals, Corp. |
EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
|
|
US6245332B1
(en)
|
1999-01-15 |
2001-06-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of systemic memory T cell trafficking
|
|
US6488930B1
(en)
|
1999-01-15 |
2002-12-03 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR4 antibodies and methods of use therefor
|
|
HK1038755A1
(zh)
|
1999-01-15 |
2002-03-28 |
Biogen, Inc. |
Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
|
|
ATE412433T1
(de)
|
1999-02-12 |
2008-11-15 |
Scripps Research Inst |
Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
|
|
US6335013B1
(en)
|
1999-03-19 |
2002-01-01 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
|
GB9907965D0
(en)
|
1999-04-09 |
1999-06-02 |
Glaxo Group Ltd |
Medical use
|
|
WO2000064946A2
(en)
|
1999-04-28 |
2000-11-02 |
Board Of Regents, The University Of Texas System |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
|
EP1048299A1
(en)
|
1999-04-28 |
2000-11-02 |
Faculteit der Geneeskunde van de Vrije Universiteit |
Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
US7129338B1
(en)
|
1999-07-08 |
2006-10-31 |
Research Association For Biotechnology |
Secretory protein or membrane protein
|
|
EP1514933A1
(en)
|
1999-07-08 |
2005-03-16 |
Research Association for Biotechnology |
Secretory protein or membrane protein
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
EP1200479B1
(en)
|
1999-08-09 |
2006-02-01 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
|
WO2001014424A2
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US6482411B1
(en)
|
1999-08-27 |
2002-11-19 |
Board Of Regents, The University Of Texas System |
Methods of reducing bone loss with CD40 ligand
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
US20030119038A1
(en)
|
1999-09-09 |
2003-06-26 |
Bingham Brendan William |
NARC1, novel subtilase-like homologs
|
|
US20100291099A1
(en)
|
1999-09-27 |
2010-11-18 |
Millennium Pharmaceuticals, Inc. |
Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
|
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
|
WO2001031007A2
(en)
|
1999-10-22 |
2001-05-03 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules derived from rat brain and programmed cell death models
|
|
US20110230392A1
(en)
|
1999-10-22 |
2011-09-22 |
Millennium Pharmaceuticals, Inc. |
Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
|
|
US20020081679A1
(en)
|
1999-10-22 |
2002-06-27 |
Millennium Pharmaceuticals, Inc. |
NARC8 programmed cell-death-associated molecules and uses thereof
|
|
GB9927757D0
(en)
|
1999-11-25 |
2000-01-26 |
Kennedy Rheumatology Inst |
Treatment of autoimmune diseases
|
|
EP1244707A1
(de)
|
1999-11-30 |
2002-10-02 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Antikörper gegen signal-regulator-proteine
|
|
AU2841101A
(en)
|
1999-12-08 |
2001-06-18 |
Novartis Ag |
Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
|
|
TWI263496B
(en)
|
1999-12-10 |
2006-10-11 |
Novartis Ag |
Pharmaceutical combinations and their use in treating gastrointestinal disorders
|
|
DE10001372A1
(de)
|
2000-01-14 |
2001-08-02 |
Deutsches Krebsforsch |
Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
AU2001241461A1
(en)
|
2000-02-07 |
2001-08-14 |
Millennium Pharmaceuticals, Inc. |
Narc-1, novel subtilase-like homologs
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
WO2001064754A1
(en)
|
2000-03-03 |
2001-09-07 |
Kyowa Hakko Kogyo Co., Ltd. |
Gene recombinant antibody and its fragment
|
|
AU2001253496A1
(en)
|
2000-04-14 |
2001-10-30 |
Millennium Pharmaceuticals, Inc. |
Treating graft rejection with cxcr3 inhibitors
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
AU2001259215A1
(en)
|
2000-04-28 |
2001-11-12 |
La Jolla Institute For Allergy And Immunology |
Human anti-cd40 antibodies and methods of making and using same
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
US6680315B2
(en)
|
2000-06-15 |
2004-01-20 |
Synta Pharmaceuticals Corp. |
Triazine compounds
|
|
CA2411971A1
(en)
|
2000-06-16 |
2001-12-27 |
Incyte Genomics, Inc. |
Proteases
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
CA2412845C
(en)
|
2000-06-29 |
2014-07-22 |
Lexigen Pharmaceuticals Corp. |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
WO2002011762A2
(en)
|
2000-08-03 |
2002-02-14 |
Gorczynski Reginald M |
Methods and compositions for modulating tumor growth
|
|
AU2001280471A1
(en)
|
2000-08-11 |
2002-02-25 |
Eli Lilly And Company |
Novel secreted proteins and their uses
|
|
ATE444761T1
(de)
|
2000-08-18 |
2009-10-15 |
Univ California |
Methoden zum behandeln von demyelinisierenden krankheiten
|
|
CN1284536C
(zh)
|
2000-09-18 |
2006-11-15 |
威克斯医药有限公司 |
河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
|
|
CN1203857C
(zh)
|
2000-09-18 |
2005-06-01 |
威克斯医药有限公司 |
局部麻醉与镇痛的新方法
|
|
US7052676B2
(en)
|
2000-09-26 |
2006-05-30 |
The Regents Of The University Of Michigan |
Methods for inhibition of HIV replication using a small molecule inhibitor
|
|
US20020064555A1
(en)
|
2000-09-29 |
2002-05-30 |
Dan Cullen |
Proton pump inhibitor formulation
|
|
WO2002028481A2
(en)
|
2000-10-02 |
2002-04-11 |
Chiron Corporation |
Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
|
|
ATE442862T2
(de)
|
2000-10-12 |
2009-10-15 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
JP4280803B2
(ja)
|
2000-12-08 |
2009-06-17 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
慢性リンパ性白血病細胞株および抗体を産生するためのその使用
|
|
US20050101529A1
(en)
|
2000-12-08 |
2005-05-12 |
Henry Yue |
Protein modification and maintenance molecules
|
|
US20040198661A1
(en)
|
2000-12-08 |
2004-10-07 |
Bowdish Katherine S. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US20040043457A1
(en)
|
2001-01-18 |
2004-03-04 |
Silke Schumacher |
Bifunctional fusion proteins with glucocerebrosidase activity
|
|
CA2438628A1
(en)
|
2001-02-19 |
2002-08-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Artificial proteins with reduced immunogenicity
|
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
|
HUP0303428A2
(hu)
|
2001-03-07 |
2004-01-28 |
Merck Patent Gmbh. |
Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
|
|
WO2003038063A2
(en)
|
2001-03-21 |
2003-05-08 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
AU2002258941A1
(en)
|
2001-04-20 |
2002-11-05 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing cell responsiveness
|
|
BR0209177A
(pt)
|
2001-05-03 |
2004-10-05 |
Merck Patent Gmbh |
Anticorpo especìfico a tumor recombinante e uso do mesmo
|
|
US7282556B2
(en)
|
2001-05-15 |
2007-10-16 |
Emory University |
Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
|
|
PT1397153E
(pt)
|
2001-05-23 |
2008-06-12 |
Bristol Myers Squibb Co |
Métodos para proteger um transplante alogénico de ilhéus utilizando moléculas mutantes de ctla4 solúveis
|
|
US20040023243A1
(en)
|
2001-06-13 |
2004-02-05 |
Yue Henry |
Proteases
|
|
IL159177A0
(en)
|
2001-06-20 |
2004-06-01 |
Prochon Biotech Ltd |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
US20030124149A1
(en)
|
2001-07-06 |
2003-07-03 |
Shalaby Shalaby W. |
Bioactive absorbable microparticles as therapeutic vaccines
|
|
US20030133936A1
(en)
|
2001-07-12 |
2003-07-17 |
Byrne Michael Chapman |
CD25markers and uses thereof
|
|
AU2002316674B2
(en)
|
2001-07-12 |
2007-09-13 |
The Regents Of The University Of California |
CXCL10 treatment of secondary tissue degeneration
|
|
US20040038242A1
(en)
|
2001-07-30 |
2004-02-26 |
Edmonds Brian Taylor |
Novel secreted proteins and their uses
|
|
CA2456470A1
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
ATE490277T1
(de)
|
2001-08-31 |
2010-12-15 |
Kyowa Hakko Kirin Co Ltd |
Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon
|
|
WO2003029296A1
(en)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Human anti-cd40 antibodies
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
EP1441759A2
(de)
|
2001-11-09 |
2004-08-04 |
MediGene Aktiengesellschaft |
Zelluläre impfstoffe mit adjuvanzien
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
|
US20050214857A1
(en)
|
2001-12-11 |
2005-09-29 |
Algonomics N.V. |
Method for displaying loops from immunoglobulin domains in different contexts
|
|
US20040009174A1
(en)
|
2001-12-18 |
2004-01-15 |
Arndt Gregory Martin |
Method of treating asthma
|
|
EP4091631A1
(en)
|
2002-01-30 |
2022-11-23 |
The Brigham and Women's Hospital, Inc. |
A tim-3 binding molecule for use in the treatment of a disease
|
|
WO2003066830A2
(en)
|
2002-02-08 |
2003-08-14 |
Genetastix Corporation |
Human monoclonal antibodies against membrane proteins
|
|
US20060093771A1
(en)
|
2002-02-15 |
2006-05-04 |
Frantisek Rypacek |
Polymer coating for medical devices
|
|
US7659082B2
(en)
|
2002-02-19 |
2010-02-09 |
Xenon Pharmaceuticals Inc. |
Methods for identifying analgesic agents
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
US6887673B2
(en)
|
2002-07-30 |
2005-05-03 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1BB
|
|
US6875433B2
(en)
|
2002-08-23 |
2005-04-05 |
The United States Of America As Represented By The Secretary Of The Army |
Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
|
|
EP1400534B1
(en)
|
2002-09-10 |
2015-10-28 |
Affimed GmbH |
Human CD3-specific antibody with immunosuppressive properties
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
JP2006500931A
(ja)
|
2002-09-30 |
2006-01-12 |
ファイザー・プロダクツ・インク |
高レベルのヒト配列抗体を産生するハイブリドーマ
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
US7919083B2
(en)
|
2002-11-15 |
2011-04-05 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
|
|
AU2003294290A1
(en)
|
2002-11-15 |
2004-06-15 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
|
|
CA2507004A1
(en)
|
2002-12-03 |
2004-06-17 |
Celltech R & D Limited |
Assay for identifying antibody producing cells
|
|
KR20050091713A
(ko)
|
2002-12-05 |
2005-09-15 |
프로테인 디자인 랩스 인코포레이티드 |
항-시디3 항체를 이용한 궤양성 대장염의 치료 방법
|
|
US20060121030A1
(en)
|
2002-12-16 |
2006-06-08 |
Herbert Schwarz |
Use of cd 137 antagonists for the treatment of tumors
|
|
RU2366664C2
(ru)
|
2002-12-17 |
2009-09-10 |
Мерк Патент Гмбх |
Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US20050002939A1
(en)
|
2002-12-23 |
2005-01-06 |
Albert Zlotnik |
Tumor killing/tumor regression using CXCR4 antagonists
|
|
CA2511513A1
(en)
|
2002-12-27 |
2004-07-22 |
Schering Corporation |
Methods of inducing and maintaining immune tolerance
|
|
AU2003299971A1
(en)
|
2002-12-30 |
2004-07-29 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
US7608260B2
(en)
|
2003-01-06 |
2009-10-27 |
Medimmune, Llc |
Stabilized immunoglobulins
|
|
EP1897548B2
(en)
|
2003-02-28 |
2024-05-22 |
The Johns Hopkins University |
T cell regulation
|
|
US20080019973A1
(en)
|
2003-03-17 |
2008-01-24 |
Lane Thomas E |
Methods for Treating Ocular Inflammation by Neutralizing Cxcl10 Activity
|
|
EP1462114A1
(en)
|
2003-03-28 |
2004-09-29 |
Universiteit Utrecht Holding B.V. |
Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
|
|
EP1618181B1
(en)
|
2003-04-22 |
2014-10-15 |
IBC Pharmaceuticals |
Polyvalent protein complex
|
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
|
WO2004101511A2
(en)
|
2003-05-09 |
2004-11-25 |
Protein Design Labs, Inc |
Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
|
|
AU2004270103B2
(en)
|
2003-05-21 |
2012-02-23 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies against Bacillusanthracis protective antigen
|
|
CA2527878A1
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
|
WO2004108158A1
(en)
|
2003-06-02 |
2004-12-16 |
Alexion Pharmaceuticals, Inc. |
De-immunized anti-cd3 antibody
|
|
JP3936673B2
(ja)
|
2003-06-02 |
2007-06-27 |
国立大学法人群馬大学 |
Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
|
|
CA2519875C
(en)
|
2003-06-06 |
2014-01-14 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with vegf inhibitors
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
CA2527020A1
(en)
|
2003-07-01 |
2005-01-13 |
Celltech R & D Limited |
Modified antibody fab fragments
|
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
PL207804B1
(pl)
|
2003-07-29 |
2011-02-28 |
Htl Strefa Społka Z Ograniczoną Odpowiedzialnością |
Przyrząd do nakłuwania
|
|
CA2534711A1
(en)
|
2003-08-01 |
2005-02-10 |
Medarex, Inc. |
Combination therapies for multiple sclerosis
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
US20050053600A1
(en)
|
2003-09-09 |
2005-03-10 |
Lane Thomas E. |
Methods for treating rheumatoid arthritis
|
|
US20050118625A1
(en)
|
2003-10-02 |
2005-06-02 |
Mounts William M. |
Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
|
|
CA2542037A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Composition of antibody capable of specifically binding ccr4
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
JP2005130764A
(ja)
|
2003-10-30 |
2005-05-26 |
Pharmaceuticals & Medical Devices Agency |
Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
|
|
DE602004028272D1
(de)
|
2003-11-04 |
2010-09-02 |
Novartis Vaccines & Diagnostic |
Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
|
|
EP1684869B1
(en)
|
2003-11-04 |
2011-07-20 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of therapy for b cell-related cancers
|
|
DK1680141T3
(da)
|
2003-11-04 |
2010-11-01 |
Novartis Vaccines & Diagnostic |
Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
|
|
AU2004287480B2
(en)
|
2003-11-04 |
2011-09-15 |
Novartis Vaccines And Diagnostics, Inc. |
Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia
|
|
DK1682180T3
(da)
|
2003-11-04 |
2010-01-11 |
Novartis Vaccines & Diagnostic |
Monoklonale antagonist-anti-CD40-antistoffer og fremgangsmåder til anvendelse deraf
|
|
WO2005060457A2
(en)
|
2003-12-04 |
2005-07-07 |
Pdl Biopharma, Inc. |
Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
|
|
DE602004029934D1
(de)
|
2003-12-04 |
2010-12-16 |
Kyowa Hakko Kirin Co Ltd |
Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
|
|
KR101333449B1
(ko)
|
2003-12-10 |
2013-11-26 |
메다렉스, 엘.엘.시. |
Ｉｐ―１０ 항체 및 그의 용도
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
JP4242388B2
(ja)
|
2003-12-25 |
2009-03-25 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の変異体
|
|
CA2551915C
(en)
|
2003-12-30 |
2015-06-23 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Il-7 fusion proteins
|
|
CA2551916C
(en)
|
2003-12-31 |
2014-04-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
CA2552590A1
(en)
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
RU2006135112A
(ru)
|
2004-03-05 |
2008-04-10 |
Чирон Корпорейшн (Us) |
Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
|
|
AU2005219322B2
(en)
|
2004-03-09 |
2008-09-18 |
Kyoto University |
Pharmaceutical Composition Comprising CXCR3 Inhibitor
|
|
MXPA06010887A
(es)
|
2004-03-23 |
2007-03-08 |
Amgen Inc |
Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano.
|
|
US7998481B2
(en)
|
2004-04-05 |
2011-08-16 |
The Regents Of The University Of California |
Modulation of NKG2D for treating or preventing solid organ allograft rejection
|
|
WO2005103086A1
(en)
|
2004-04-23 |
2005-11-03 |
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
|
MXPA06012430A
(es)
|
2004-04-27 |
2007-04-19 |
Novartis Vaccines & Diagnostic |
Anticuerpos monoclonales antagonistas anti-cd40 y metodos para su uso.
|
|
GB0411186D0
(en)
|
2004-05-19 |
2004-06-23 |
Celltech R&D Ltd |
Biological products
|
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
|
BRPI0511782B8
(pt)
|
2004-06-03 |
2021-05-25 |
Novimmune Sa |
anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
|
|
GB0412986D0
(en)
|
2004-06-10 |
2004-07-14 |
Xention Discovery Ltd |
Compounds
|
|
US20050281822A1
(en)
|
2004-06-18 |
2005-12-22 |
Cedarbaum Jesse M |
Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
|
|
EP1768695A4
(en)
|
2004-06-29 |
2008-07-30 |
Univ Johns Hopkins |
IMPROVEMENT OF MEDICINE-INDUCED TOXICITY
|
|
US20090252741A1
(en)
|
2004-09-08 |
2009-10-08 |
Ohio State University Research Foundation |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
|
CN101023102B
(zh)
|
2004-09-17 |
2013-05-29 |
霍夫曼-拉罗奇有限公司 |
抗-ox40l抗体
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
SI1810026T1
(en)
|
2004-10-06 |
2018-08-31 |
Mayo Foundation For Medical Education And Research |
B7-H1 and PD-1 in the treatment of renal cell carcinoma
|
|
WO2006039819A1
(en)
|
2004-10-15 |
2006-04-20 |
St. Michael's Hospital |
Markers of lung injury
|
|
CA2585776A1
(en)
|
2004-10-29 |
2006-05-11 |
University Of Southern California |
Combination cancer immunotherapy with co-stimulatory molecules
|
|
KR20070067702A
(ko)
|
2004-11-04 |
2007-06-28 |
화이자 프로덕츠 인크. |
유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법
|
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
|
AU2005313492B2
(en)
|
2004-12-09 |
2011-12-15 |
Merck Patent Gmbh |
IL-7 variants with reduced immunogenicity
|
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
|
JP2008532936A
(ja)
|
2005-02-14 |
2008-08-21 |
ワイス |
インターロイキン−１７ｆ抗体及び他のｉｌ−１７ｆシグナル伝達拮抗物質並びにそれらの使用
|
|
EP1871807B1
(en)
|
2005-02-18 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cxcr4 and methods of use thereof
|
|
US7981605B2
(en)
|
2005-02-24 |
2011-07-19 |
Amgen Inc. |
Epidermal growth factor receptor mutations
|
|
AR054233A1
(es)
|
2005-03-08 |
2007-06-13 |
Pharmacia & Upjohn Co Llc |
Composiciones de anticuerpos igg2
|
|
WO2006099154A1
(en)
|
2005-03-11 |
2006-09-21 |
Regeneron Pharmaceuticals, Inc. |
Treating anemia by inhibition of vegf
|
|
AU2006227880A1
(en)
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
|
|
AR053690A1
(es)
|
2005-03-23 |
2007-05-16 |
Pfizer Prod Inc |
Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal
|
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
|
EP1891972A1
(en)
|
2005-04-26 |
2008-02-27 |
Stelic Institute of Regenerative Medicine |
Agent for promoting hepatic cell replication and agent for improving insulin resistance
|
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
|
|
US8303955B2
(en)
|
2005-05-26 |
2012-11-06 |
Seattle Genetics, Inc. |
Humanized anti-CD40 antibodies and their methods of use
|
|
MX349137B
(es)
|
2005-06-08 |
2017-07-13 |
Dana-Farber Cancer Inst |
Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
CA2617539A1
(en)
|
2005-07-01 |
2007-01-11 |
Washington University In St. Louis |
Phosphospecific chemokine receptor antibodies
|
|
EA200800268A1
(ru)
|
2005-07-07 |
2008-06-30 |
Коли Фармасьютикал Груп, Инк. |
КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
|
|
CN101237880B
(zh)
|
2005-08-12 |
2011-09-21 |
瑞泽恩制药公司 |
通过vegf拮抗剂的皮下给药治疗疾病
|
|
GB0517487D0
(en)
|
2005-08-26 |
2005-10-05 |
Isis Innovation |
Antibodies
|
|
US7972813B2
(en)
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
|
JP2009517339A
(ja)
|
2005-11-01 |
2009-04-30 |
ノバルティス アーゲー |
抗ｃｄ４０抗体の使用
|
|
EP1957538B1
(en)
|
2005-11-01 |
2013-05-22 |
Novartis AG |
Uses of anti-cd40 antibodies
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
AR057253A1
(es)
|
2005-12-16 |
2007-11-21 |
Genentech Inc |
Anticuerpos anti-ox40l y metodos que los utilizan
|
|
TWI423986B
(zh)
|
2005-12-20 |
2014-01-21 |
必治妥美雅史谷比公司 |
組合物及製造組合物之方法
|
|
BRPI0707126A2
(pt)
|
2006-01-12 |
2011-04-19 |
Alexion Pharma Inc |
anticorpos para ox-2/cd200 e uso destes
|
|
EP1981969A4
(en)
|
2006-01-19 |
2009-06-03 |
Genzyme Corp |
ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
|
|
WO2007109324A2
(en)
|
2006-03-21 |
2007-09-27 |
Xenon Pharmaceuticals, Inc. |
Potent and selective nav 1.7 sodium channel blockers
|
|
EP2001509A1
(en)
|
2006-04-03 |
2008-12-17 |
Medizinische Hochschule Hannover |
Pharmaceuticals for influencing the reaction of the human immune system
|
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
AU2007240507B2
(en)
|
2006-04-21 |
2013-07-18 |
Novartis Ag |
Antagonist anti-CD40 antibody pharmaceutical compositions
|
|
EP2589654A1
(en)
|
2006-05-03 |
2013-05-08 |
The Regents of the University of Colorado, a body corporate |
CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
|
EP2348106B1
(en)
|
2006-05-08 |
2014-07-02 |
Adaerata, Limited Partnership |
Chimeric proteins, cells comprising same, and assays using same
|
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
EP2835429B1
(en)
|
2006-05-11 |
2017-12-13 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
AU2007271398B2
(en)
|
2006-07-06 |
2013-06-20 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
|
|
KR101374983B1
(ko)
|
2006-08-28 |
2014-03-17 |
라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 |
길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
|
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
|
RS55740B1
(sr)
|
2006-10-02 |
2017-07-31 |
Squibb & Sons Inc |
Humana antitela koja se vezuju za cxcr4 i njihove upotrebe
|
|
WO2008044824A1
(en)
|
2006-10-13 |
2008-04-17 |
Seoul National University Industry Foundation |
Antibodies to ip-10 for treating bone diseases with bone destruction
|
|
JP2010013355A
(ja)
|
2006-10-19 |
2010-01-21 |
Stelic Institute Of Regenerative Medicine |
心筋障害抑制剤
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
US20100068194A1
(en)
|
2006-10-24 |
2010-03-18 |
Dong-Ku Kim |
Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
|
|
WO2008133647A2
(en)
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
EP2083860A4
(en)
|
2006-11-07 |
2010-05-26 |
Merck Sharp & Dohme |
PCSK9 ANTAGONISTS
|
|
EP2083859A4
(en)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
PCSK9 ANTAGONISTS
|
|
EP2083861A4
(en)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
ANTAGONISTS OF PCSK9
|
|
NZ577085A
(en)
|
2006-11-15 |
2012-06-29 |
Medarex Inc |
Human monoclonal antibodies to btla and methods of use
|
|
WO2008073316A2
(en)
|
2006-12-07 |
2008-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Identification and isolation of acute myeloid leukemia stem cells
|
|
WO2008083169A2
(en)
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
|
EP2133365B1
(en)
|
2006-12-27 |
2017-05-17 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
AU2008204901A1
(en)
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-IL-13 antibody formulations and uses thereof
|
|
JP5357778B2
(ja)
|
2007-01-23 |
2013-12-04 |
ゼンコー・インコーポレイテッド |
最適化ｃｄ４０抗体および前記を使用する方法
|
|
WO2008090958A1
(ja)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
ドメイン交換された遺伝子組換え抗体組成物
|
|
US20100136030A1
(en)
|
2007-02-27 |
2010-06-03 |
Lamhamedi-Cherradi Salah-Eddine |
Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
|
AU2008219570B2
(en)
|
2007-02-28 |
2013-08-22 |
Novimmune Sa |
Human anti-IP-10 antibodies and uses thereof
|
|
WO2008109871A2
(en)
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
|
CN101679527A
(zh)
|
2007-04-13 |
2010-03-24 |
诺瓦提斯公司 |
用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
|
|
MX2009011226A
(es)
|
2007-04-17 |
2010-04-01 |
Imclone Llc |
Inhibidores especificos pdgfrbeta.
|
|
FR2915102B1
(fr)
|
2007-04-23 |
2014-05-16 |
Pf Medicament |
Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
WO2008156712A1
(en)
|
2007-06-18 |
2008-12-24 |
N. V. Organon |
Antibodies to human programmed death receptor pd-1
|
|
WO2009009547A2
(en)
|
2007-07-09 |
2009-01-15 |
Qualcomm Incorporated |
Methods for sending small packets in a peer-to-peer (p2p) network
|
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
AU2008275589B2
(en)
|
2007-07-12 |
2013-11-21 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
USRE46323E1
(en)
|
2007-07-25 |
2017-02-28 |
Alexion Pharmaceuticals, Inc. |
Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
|
|
AU2008287063B2
(en)
|
2007-08-09 |
2013-10-24 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
WO2009026303A1
(en)
|
2007-08-21 |
2009-02-26 |
Amgen Inc. |
Human c-fms antigen binding proteins
|
|
US20130072665A1
(en)
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
|
EP2573112A1
(en)
|
2007-10-11 |
2013-03-27 |
The Hospital For Sick Children |
Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
|
JP2011501952A
(ja)
|
2007-10-26 |
2011-01-20 |
シェーリング コーポレイション |
脂質障害およびコレステロール障害を治療するための抗ｐｃｓｋ９および方法
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
US9068230B2
(en)
|
2007-11-07 |
2015-06-30 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
|
|
RU2491095C2
(ru)
|
2007-11-09 |
2013-08-27 |
Новартис Аг |
Применения анти-cd40-антител
|
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
|
CA2712989C
(en)
|
2008-01-23 |
2015-10-27 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
EP3153526B1
(en)
|
2008-01-31 |
2020-09-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
US8263073B2
(en)
|
2008-02-04 |
2012-09-11 |
Medarex, Inc. |
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
AR070316A1
(es)
*
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
NZ587830A
(en)
|
2008-03-14 |
2012-08-31 |
Transgene Sa |
Antibody against the colony-stimulating factor-1 receptor (CSF-1R)
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
EP2252318A4
(en)
|
2008-03-20 |
2012-04-18 |
Carolus Therapeutics Inc |
PROCESS FOR TREATMENT OF IGNITION
|
|
US9176122B2
(en)
|
2008-03-24 |
2015-11-03 |
University Of South Florida |
Biomarkers for predicting response to immunosuppressive therapy
|
|
WO2009120186A1
(en)
|
2008-03-24 |
2009-10-01 |
Carolus Therapeutics, Inc. |
Methods and compositions for treating atherosclerosis and related conditions
|
|
ES2758126T3
(es)
|
2008-04-09 |
2020-05-04 |
Genentech Inc |
Composiciones y métodos para el tratamiento de enfermedades relacionadas con la inmunidad
|
|
WO2009131740A2
(en)
|
2008-04-23 |
2009-10-29 |
Amgen Inc. |
Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
|
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
|
CA2723143A1
(en)
|
2008-05-01 |
2009-11-05 |
Martin G. Sanda |
Methods and compositions for prostate cancer immunotherapy
|
|
CA2724409A1
(en)
|
2008-05-14 |
2009-11-19 |
Eli Lilly And Company |
Anti-cxcr4 antibodies
|
|
BRPI0911984A2
(pt)
|
2008-05-16 |
2016-09-20 |
Ablynx Nv |
sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
|
|
WO2009141239A1
(en)
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
|
WO2010001908A1
(ja)
|
2008-06-30 |
2010-01-07 |
協和発酵キリン株式会社 |
抗cd27抗体
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
CA2735421A1
(en)
|
2008-08-29 |
2010-03-04 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Delivery of a cd40 agonist to a tumor draining lymph node of a subject
|
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Ｐｃｓｋ９拮抗劑類
|
|
WO2010029435A1
(en)
|
2008-09-12 |
2010-03-18 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
EP2342228B1
(en)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
SG2014011365A
(en)
|
2008-09-19 |
2014-05-29 |
Hoffmann La Roche |
Novel antibody formulation
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
CA2737241C
(en)
|
2008-09-26 |
2017-08-29 |
Ucb Pharma S.A. |
Multivalent antibody fusion proteins
|
|
EP2172485A1
(en)
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
|
CA2742968C
(en)
|
2008-11-07 |
2020-06-09 |
Fabrus Llc |
Combinatorial antibody libraries and uses thereof
|
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン，エルエルシー |
抗体製剤
|
|
TW202442680A
(zh)
|
2008-12-09 |
2024-11-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
EP2382722B1
(en)
|
2008-12-23 |
2012-05-30 |
Koninklijke Philips Electronics N.V. |
Combining body-coupled communication and radio frequency communication
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
PT2398498T
(pt)
|
2009-02-17 |
2018-12-03 |
Ucb Biopharma Sprl |
Moléculas de anticorpo tendo especificidade para ox40 humano
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
AU2010222942B2
(en)
|
2009-03-10 |
2013-01-10 |
Baylor Research Institute |
Anti-CD40 antibodies and uses thereof
|
|
CN103415534A
(zh)
|
2009-03-10 |
2013-11-27 |
贝勒研究院 |
靶向抗原呈递细胞的癌症疫苗
|
|
WO2010106051A1
(en)
|
2009-03-17 |
2010-09-23 |
Universite De La Mediterranee |
Btla antibodies and uses thereof
|
|
CA2756186A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
|
WO2010117448A2
(en)
|
2009-04-05 |
2010-10-14 |
Provenance Biopharmaceuticals Corp. |
Chimeric immunocytokines and methods of use thereof
|
|
CA2758523C
(en)
|
2009-04-18 |
2019-03-12 |
Genentech, Inc. |
Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
|
|
HUE028537T2
(en)
|
2009-04-20 |
2016-12-28 |
Kyowa Hakko Kirin Co Ltd |
Built-in amino acid mutation IgG2 antibody
|
|
EP2246364A1
(en)
|
2009-04-29 |
2010-11-03 |
Pierre Fabre Médicament |
Anti CXCR4 antibodies for the treatment of HIV
|
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
|
CA2766608C
(en)
|
2009-07-06 |
2018-06-19 |
F. Hoffmann-La Roche Ag |
Bi-specific digoxigenin binding antibodies
|
|
NO2792236T3
(cg-RX-API-DMAC7.html)
|
2009-07-08 |
2018-04-14 |
|
|
|
MX2012001417A
(es)
|
2009-07-31 |
2012-07-03 |
Organon Nv |
Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla).
|
|
CA2769822C
(en)
|
2009-08-13 |
2019-02-19 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
KR20120053042A
(ko)
|
2009-08-17 |
2012-05-24 |
로슈 글리카트 아게 |
표적화된 면역접합체
|
|
EP2473186A4
(en)
|
2009-08-31 |
2013-07-10 |
Ibc Pharmaceuticals Inc |
BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF
|
|
IN2012DN01920A
(cg-RX-API-DMAC7.html)
|
2009-09-03 |
2015-07-24 |
Schering Corp |
|
|
US20120283116A1
(en)
|
2009-09-11 |
2012-11-08 |
Leppert Mark F |
Mutant Sodium Channel Nav1.7 and Methods Related Thereto
|
|
US20120219558A1
(en)
|
2009-09-25 |
2012-08-30 |
Yan Ni |
Antagonists of pcsk9
|
|
AU2010303149B2
(en)
|
2009-09-30 |
2016-08-04 |
Board Of Regents, The University Of Texas System |
Combination immunotherapy for the treatment of cancer
|
|
EP2486056A1
(en)
|
2009-10-09 |
2012-08-15 |
Ablynx N.V. |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
|
JP6095368B2
(ja)
|
2009-10-27 |
2017-03-15 |
ユセベ ファルマ ソシエテ アノニム |
機能改変するＮａｖ１．７抗体
|
|
WO2011053759A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax1 and ax189 pcsk9 antagonists and variants
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
US20120208209A1
(en)
|
2009-10-30 |
2012-08-16 |
Marina Ichetovkin |
Pcsk9 immunoassay
|
|
WO2011053665A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
|
CN102639150A
(zh)
|
2009-10-30 |
2012-08-15 |
默沙东公司 |
Ax213和ax132 pcsk9拮抗剂和变体
|
|
US20120316071A1
(en)
|
2009-11-04 |
2012-12-13 |
Vaughn Smider |
Methods for affinity maturation-based antibody optimization
|
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
|
AU2010328347B2
(en)
|
2009-12-07 |
2015-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for enhancing anti-tumor antibody therapy
|
|
CN105218672A
(zh)
|
2009-12-10 |
2016-01-06 |
霍夫曼-拉罗奇有限公司 |
优先结合人csf1r胞外域4的抗体及其用途
|
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
US8962807B2
(en)
|
2009-12-14 |
2015-02-24 |
Ablynx N.V. |
Single variable domain antibodies against OX40L, constructs and therapeutic use
|
|
TW201130511A
(en)
|
2009-12-22 |
2011-09-16 |
Novartis Ag |
Soluble proteins for use as therapeutics
|
|
EP2520589B1
(en)
|
2009-12-29 |
2018-11-07 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
EP2531216B1
(en)
|
2010-02-04 |
2019-03-27 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
|
JP2013519682A
(ja)
|
2010-02-11 |
2013-05-30 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
抗ｃｄ２００抗体を使用する治療方法
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
AU2011225716A1
(en)
|
2010-03-11 |
2012-09-27 |
Pfizer Inc. |
Antibodies with pH dependent antigen binding
|
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
|
EP2371863A1
(en)
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Humanized anti CXCR4 antibodies for the treatment of cancer
|
|
SI3178851T1
(sl)
|
2010-03-31 |
2020-09-30 |
Boehringer Inhelheim International Gmbh |
Anti-CD40 protitelesa
|
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
US9169325B2
(en)
|
2010-04-13 |
2015-10-27 |
Celldex Therapeutics, Inc. |
Antibodies that bind human CD27 and uses thereof
|
|
EA022983B1
(ru)
|
2010-04-13 |
2016-04-29 |
Бристол-Майерс Сквибб Компани |
Белки на основе структурного домена фибронектина, связывающие pcsk9
|
|
MX340683B
(es)
|
2010-04-16 |
2016-07-21 |
Biogen Ma Inc |
Anticuerpos anti-vla-4.
|
|
CN112480256A
(zh)
|
2010-05-04 |
2021-03-12 |
戊瑞治疗有限公司 |
结合csf1r的抗体
|
|
US8486647B2
(en)
|
2010-06-09 |
2013-07-16 |
Regeneron Pharmaceuticals, Inc. |
Neuropeptide release assay for sodium channels
|
|
US8871996B2
(en)
|
2010-06-09 |
2014-10-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing human voltage-gated sodium channels
|
|
JP6158511B2
(ja)
|
2010-06-11 |
2017-07-05 |
協和発酵キリン株式会社 |
抗ｔｉｍ−３抗体
|
|
CN105695415A
(zh)
|
2010-06-17 |
2016-06-22 |
科马布有限公司 |
动物模型及治疗分子
|
|
WO2011161266A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
EP3696195B1
(en)
*
|
2010-07-23 |
2024-02-14 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
|
ES2630328T3
(es)
|
2010-08-23 |
2017-08-21 |
Board Of Regents, The University Of Texas System |
Anticuerpos anti-OX40 y procedimientos de uso de los mismos
|
|
RU2013110874A
(ru)
|
2010-08-25 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против il-18r1 и их применения
|
|
DK2614082T3
(en)
|
2010-09-09 |
2018-11-26 |
Pfizer |
4-1BB BINDING MOLECULES
|
|
EP2618656B1
(en)
|
2010-09-20 |
2018-06-20 |
Yale University, Inc. |
HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
|
|
AU2011310887A1
(en)
|
2010-09-29 |
2013-05-02 |
Universite De Liege |
Combination of an agonistic anti-CD40 monoclonal antibody or a CD40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
|
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
|
JP2014504147A
(ja)
|
2010-10-27 |
2014-02-20 |
ピエール、ファーブル、メディカマン |
Ｈｉｖの治療用抗体
|
|
EP3575321B1
(en)
|
2010-11-08 |
2023-07-26 |
Ablynx N.V. |
Cxcr2 binding polypeptides
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
|
GB201020738D0
(en)
|
2010-12-07 |
2011-01-19 |
Affitech Res As |
Antibodies
|
|
EP2655409A4
(en)
|
2010-12-22 |
2015-07-01 |
Univ Leland Stanford Junior |
SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
|
|
US20130273062A1
(en)
|
2010-12-22 |
2013-10-17 |
Orega Biotech |
Antibodies against human cd39 and use thereof
|
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
|
WO2012099983A1
(en)
|
2011-01-18 |
2012-07-26 |
Amgen Inc. |
Nav1.7 knockout mice and uses thereof
|
|
AR084938A1
(es)
|
2011-01-28 |
2013-07-10 |
Sanofi Sa |
Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
|
|
EP2481758A1
(en)
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
US20120258073A1
(en)
|
2011-02-10 |
2012-10-11 |
Christian Gerdes |
Immunotherapy
|
|
HUE040326T2
(hu)
|
2011-02-10 |
2019-03-28 |
Roche Glycart Ag |
Mutáns interleukon-2 polipeptidek
|
|
JP2014511378A
(ja)
|
2011-02-11 |
2014-05-15 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Ｐｃｓｋ９アンタゴニスト
|
|
US9125893B2
(en)
|
2011-02-17 |
2015-09-08 |
Kyowa Hakko Kirin Co., Ltd. |
Highly concentrated anti-CD40 antibody pharmaceutical preparation
|
|
WO2012132067A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
ES2733646T3
(es)
|
2011-03-11 |
2019-12-02 |
Beth Israel Deaconess Medical Ct Inc |
Anticuerpos anti-CD40 y usos de los mismos
|
|
DK2691112T3
(en)
|
2011-03-31 |
2018-07-30 |
Merck Sharp & Dohme |
STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
|
|
CN106749662B
(zh)
|
2011-03-31 |
2021-06-18 |
国家医疗保健研究所 |
抗icos的抗体及其用途
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
|
DK2699601T3
(en)
|
2011-04-21 |
2018-04-23 |
Bristol Myers Squibb Co |
ANTIBODY POLYPEPTIDES ANTAGONIZING CD40
|
|
MX2013012284A
(es)
|
2011-04-29 |
2013-11-21 |
Bristol Myers Squibb Co |
Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
SG194701A1
(en)
|
2011-04-29 |
2013-12-30 |
Apexigen Inc |
Anti-cd40 antibodies and methods of use
|
|
US9732196B2
(en)
|
2011-05-10 |
2017-08-15 |
Sabic Global Technologies B.V. |
Adhesive for bonding polyimide resins
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
CN107722124A
(zh)
|
2011-05-21 |
2018-02-23 |
宏观基因有限公司 |
能够与人和非人cd3结合的cd3结合分子
|
|
WO2012162583A1
(en)
|
2011-05-26 |
2012-11-29 |
Ibc Pharmaceuticals, Inc. |
Design and construction of novel multivalent antibodies
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
|
EP2720718A4
(en)
|
2011-06-14 |
2015-01-21 |
Mayo Foundation |
ANTI-CD3 THERAPIES
|
|
CA2841416A1
(en)
|
2011-06-15 |
2012-12-20 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Method of selecting therapeutic indications
|
|
BR112013031762A2
(pt)
|
2011-06-16 |
2016-09-13 |
Novartis Ag |
proteínas solúveis para utilização como terapêuticos
|
|
WO2012177788A1
(en)
|
2011-06-20 |
2012-12-27 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
|
JP2014519848A
(ja)
|
2011-06-20 |
2014-08-21 |
ジェネンテック， インコーポレイテッド |
Ｐｃｓｋ９結合ポリペプチドと使用方法
|
|
WO2012178137A1
(en)
|
2011-06-24 |
2012-12-27 |
Gillies Stephen D |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
CN107915775B
(zh)
|
2011-07-11 |
2022-07-12 |
伊克诺斯科学公司 |
结合ox40的抗体及其用途
|
|
EP2731623A1
(en)
|
2011-07-14 |
2014-05-21 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
|
CA2842169A1
(en)
|
2011-07-20 |
2013-01-24 |
Medimmune Limited |
Anti-cxcr4 antibodies and methods of use
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087364A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
|
AR087363A1
(es)
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
|
|
EP2748199B1
(en)
|
2011-08-23 |
2019-08-28 |
Board of Regents, The University of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
ES2773111T3
(es)
|
2011-09-16 |
2020-07-09 |
Regeneron Pharma |
Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
EP2758535B1
(en)
|
2011-09-19 |
2016-11-09 |
Kymab Limited |
Antibodies, variable domains&chains tailored for human use
|
|
SMT202000091T1
(it)
|
2011-10-13 |
2020-05-08 |
Bristol Myers Squibb Co |
Polipeptidi anticorpali che antagonizzano cd40l
|
|
WO2013056352A1
(en)
|
2011-10-19 |
2013-04-25 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
|
HK1200032A1
(en)
|
2011-10-21 |
2015-07-31 |
Transgene Sa |
Modulation of macrophage activation
|
|
CN104136047B
(zh)
|
2011-10-26 |
2018-02-06 |
安姆根有限公司 |
减少或消除由暴露于uv光而引起的蛋白质修饰和降解的方法
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
DK2776032T3
(en)
|
2011-11-09 |
2019-02-04 |
Bristol Myers Squibb Co |
TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH ANTI-CXCR4 ANTIBODY
|
|
US20130115171A1
(en)
|
2011-11-09 |
2013-05-09 |
Stefan I. McDonough |
Nav1.7-related assays
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
MX349096B
(es)
*
|
2011-11-28 |
2017-07-11 |
Merck Patent Gmbh |
Anticuerpos anti-pd-l1 y sus usos.
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CA2853889A1
(en)
|
2011-12-15 |
2013-06-20 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
EP2812022B1
(en)
|
2012-02-06 |
2019-06-26 |
Providence Health & Services - Oregon |
Method of monitoring cancer treatment using ox40 agonists
|
|
GB201203442D0
(en)
*
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
CN104284678B
(zh)
|
2012-03-15 |
2018-04-24 |
詹森生物科技公司 |
人抗cd27抗体、方法和用途
|
|
WO2013148350A2
(en)
|
2012-03-26 |
2013-10-03 |
Sanofi |
Anti-light antibody therapy for inflammatory bowel disease
|
|
WO2013148284A1
(en)
|
2012-03-29 |
2013-10-03 |
Genentech, Inc. |
Antibodies that bind to a pcsk9 cleavage site and methods of use
|
|
US10202452B2
(en)
|
2012-04-20 |
2019-02-12 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
HK1207655A1
(en)
|
2012-05-04 |
2016-02-05 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
JP2015517490A
(ja)
|
2012-05-11 |
2015-06-22 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
CN103417967B
(zh)
|
2012-05-15 |
2017-05-10 |
中国医学科学院基础医学研究所 |
Cxcl‑10抑制剂在制备治疗和/或预防肺损伤的药物中的用途
|
|
WO2013172933A1
(en)
|
2012-05-15 |
2013-11-21 |
University Of Southern California |
Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
|
|
EA037351B8
(ru)
|
2012-05-15 |
2021-04-29 |
Бристол-Майерс Сквибб Компани |
Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
|
|
WO2013170367A1
(en)
|
2012-05-17 |
2013-11-21 |
The University Of British Columbia |
Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
|
|
US9102751B2
(en)
|
2012-05-18 |
2015-08-11 |
Janssen Biotech, Inc. |
Huwentoxin-IV variants and methods of use
|
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
ES2672974T3
(es)
|
2012-06-01 |
2018-06-19 |
Ibc Pharmaceuticals, Inc. |
Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
|
|
WO2013184912A2
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
|
CA2915412A1
(en)
|
2012-06-14 |
2013-12-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (cd3)
|
|
US10301389B2
(en)
|
2012-06-15 |
2019-05-28 |
Imaginab, Inc. |
Antigen binding constructs to CD3
|
|
WO2014003742A1
(en)
|
2012-06-27 |
2014-01-03 |
Morehouse School Of Medicine |
Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
|
|
US20140005352A1
(en)
|
2012-06-29 |
2014-01-02 |
Invista North America S.A R.L. |
Gas scrubber and related processes
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
DE102012013637A1
(de)
|
2012-07-09 |
2014-01-09 |
Iwis Motorsysteme Gmbh & Co. Kg |
Triebstockplanetengetriebe
|
|
EP2879709B1
(en)
|
2012-07-31 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Modulation of the immune response
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
BR112015004426A2
(pt)
|
2012-08-31 |
2018-08-28 |
Five Prime Therapeutics, Inc. |
método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória
|
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
|
WO2014043708A1
(en)
|
2012-09-17 |
2014-03-20 |
Traber Peter G |
Method for enhancing specific immunotherapies in cancer treatment
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
CN104994873B
(zh)
|
2012-10-04 |
2017-12-22 |
达纳－法伯癌症研究所公司 |
人单克隆抗‑pd‑l1抗体和使用方法
|
|
JPWO2014065402A1
(ja)
|
2012-10-26 |
2016-09-08 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
KR102270618B1
(ko)
|
2012-10-30 |
2021-06-30 |
아펙시젠, 인코포레이티드 |
항-cd40 항체 및 사용 방법
|
|
EP2938635A1
(en)
|
2012-11-09 |
2015-11-04 |
Transgene SA |
Modulation of monocytes, or precursors thereof, differentiation
|
|
SMT201900242T1
(it)
|
2012-12-03 |
2019-05-10 |
Bristol Myers Squibb Co |
Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
|
|
HK1210964A1
(en)
|
2012-12-04 |
2016-05-13 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
MX2015008117A
(es)
*
|
2012-12-21 |
2016-03-31 |
Amplimmune Inc |
Anticuerpos anti-h7cr.
|
|
AR093984A1
(es)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014110258A1
(en)
|
2013-01-09 |
2014-07-17 |
Podack Eckhard R |
Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
|
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
ES2774549T3
(es)
|
2013-03-13 |
2020-07-21 |
Bioasis Technologies Inc |
Fragmentos de P97 y usos de los mismos
|
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
|
RS56531B1
(sr)
|
2013-03-14 |
2018-02-28 |
Bristol Myers Squibb Co |
Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene
|
|
US10072076B2
(en)
|
2013-03-14 |
2018-09-11 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to NAv1.7
|
|
US9097712B2
(en)
|
2013-03-15 |
2015-08-04 |
Allied Innovative Systems Llc |
Flow-through cell counting assay
|
|
IL240838B
(en)
|
2013-03-15 |
2022-09-01 |
Glaxosmithkline Ip Dev Ltd |
Anti-3–lag binding proteins
|
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
|
JP2016515544A
(ja)
|
2013-03-18 |
2016-05-30 |
バイオセルオーエックス プロダクツ ビー．ブイ． |
ヒト化抗ｃｄ１３４（ｏｘ４０）抗体およびその使用
|
|
CN105307725B
(zh)
|
2013-04-11 |
2020-06-16 |
布里格姆及妇女医院股份有限公司 |
治疗自身免疫疾病的方法和组合物
|
|
WO2014170317A1
(en)
|
2013-04-17 |
2014-10-23 |
Morphosys Ag |
Antibodies targeting specifically human cxcr2
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
ES2845609T3
(es)
|
2013-05-02 |
2021-07-27 |
Anaptysbio Inc |
Anticuerpos dirigidos contra muerte programada-1 (PD-1)
|
|
EP3000827B1
(en)
|
2013-05-22 |
2020-04-22 |
Seoul National University Hospital |
Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof
|
|
CN106414489A
(zh)
|
2013-05-24 |
2017-02-15 |
米迪缪尼有限公司 |
抗-b7-h5抗体及其用途
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
JP6563906B2
(ja)
|
2013-05-31 |
2019-08-21 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｐｄ−１に結合する抗原結合蛋白質
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
IL311371B2
(en)
|
2013-07-05 |
2024-09-01 |
Genmab As |
CD3 antibodies of human origin or chimeras
|
|
NZ717476A
(en)
|
2013-08-01 |
2022-04-29 |
Univ Catholique Louvain |
Anti-garp protein and uses thereof
|
|
JP6506280B2
(ja)
|
2013-08-02 |
2019-05-08 |
ファイザー・インク |
抗ｃｘｃｒ４抗体および抗体−薬剤コンジュゲート
|
|
BR112016001420A2
(pt)
|
2013-08-02 |
2018-01-23 |
Aduro Biotech Holdings Europe B V |
combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
SI3036258T1
(sl)
|
2013-08-22 |
2023-11-30 |
The Council Of The Queensland Institute Of Medical Research |
Modulacija imunoreceptorjev za zdravljenje raka in virusnih infekcij
|
|
CN105636983A
(zh)
|
2013-08-22 |
2016-06-01 |
昆士兰医学研究所理事会 |
用于治疗癌症和病毒感染的免疫受体调节
|
|
GB201315486D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
KR102661249B1
(ko)
|
2013-09-11 |
2024-04-25 |
메디뮨 리미티드 |
종양 치료용 항-ｂ7-ｈ1 항체
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
|
US10081681B2
(en)
|
2013-09-20 |
2018-09-25 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
GB201317622D0
(en)
|
2013-10-04 |
2013-11-20 |
Star Biotechnology Ltd F |
Cancer biomarkers and uses thereof
|
|
CN104558177B
(zh)
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
|
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
|
EP3599248A1
(en)
|
2013-11-06 |
2020-01-29 |
Bristol-Myers Squibb Company |
Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
ES2769778T3
(es)
|
2013-12-13 |
2020-06-29 |
Swedish Stromabio Ab |
Composiciones inmunomoduladoras
|
|
CN106029696B
(zh)
|
2013-12-17 |
2020-07-28 |
基因泰克公司 |
抗cd3抗体及使用方法
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
AU2014368449C1
(en)
|
2013-12-20 |
2021-05-06 |
Intervet International B.V. |
Canine antibodies with modified CH2-CH3 sequences
|
|
IL301714A
(en)
|
2013-12-24 |
2023-05-01 |
Janssen Pharmaceutica Nv |
Antibodies and anti-VISTA fragments
|
|
KR102056963B1
(ko)
|
2013-12-30 |
2019-12-17 |
에피맙 바이오테라퓨틱스 인코포레이티드 |
Fabs-인-탠덤 면역글로불린 및 이의 용도
|
|
WO2015109124A2
(en)
|
2014-01-15 |
2015-07-23 |
Kadmon Corporation, Llc |
Immunomodulatory agents
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
RS62788B1
(sr)
|
2014-01-28 |
2022-02-28 |
Bristol Myers Squibb Co |
Anti-lag-3 antitela za lečenje hematoloških maligniteta
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
HRP20190028T1
(hr)
|
2014-02-06 |
2019-02-22 |
F. Hoffmann - La Roche Ag |
Interleukin-2 fuzijski proteini i njihove primjene
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US10435475B2
(en)
|
2014-03-07 |
2019-10-08 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize CD40 to treat IBD
|
|
CA2939293C
(en)
|
2014-03-11 |
2023-10-03 |
The Board Of Trustees Of The Leland Standford Junior University |
Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
KR102248804B1
(ko)
*
|
2014-03-12 |
2021-05-11 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
|
WO2015153513A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
US20150307620A1
(en)
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
CN106659757B
(zh)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
白介素2的超级激动剂、部分激动剂和拮抗剂
|
|
WO2015169811A2
(en)
|
2014-05-06 |
2015-11-12 |
Medimmune Limited |
Anti-cxc chemokine receptor-2 binding molecules and uses thereof
|
|
PL3142751T3
(pl)
|
2014-05-13 |
2019-12-31 |
Medimmune Limited |
Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
|
|
CN106413751A
(zh)
|
2014-05-21 |
2017-02-15 |
辉瑞大药厂 |
用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
CA2949998A1
(en)
|
2014-05-28 |
2015-12-03 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
ES2753360T3
(es)
|
2014-05-29 |
2020-04-08 |
Spring Bioscience Corp |
Anticuerpos contra PD-L1 y usos de los mismos
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
WO2015198312A1
(en)
|
2014-06-24 |
2015-12-30 |
Ccam Therapeutics Ltd. |
Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
|
|
KR102130600B1
(ko)
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
ES2916923T3
(es)
|
2014-07-11 |
2022-07-06 |
Ventana Med Syst Inc |
Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
|
|
BR122020025583B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
CN107074951B
(zh)
|
2014-08-04 |
2021-08-03 |
贝勒研究院 |
拮抗性抗-ox40l抗体及其使用方法
|
|
US10435470B2
(en)
|
2014-08-05 |
2019-10-08 |
Cb Therapeutics, Inc. |
Anti-PD-L1 antibodies
|
|
EP3552665A3
(en)
|
2014-08-12 |
2019-12-18 |
Alligator Bioscience AB |
Antibodies
|
|
KR20170035945A
(ko)
|
2014-08-14 |
2017-03-31 |
에프. 호프만-라 로슈 아게 |
인간 cd40을 활성화시키는 항체 및 인간 pd-l1에 대한 항체의 병용 요법
|
|
WO2016028810A1
(en)
|
2014-08-18 |
2016-02-25 |
Biogen Ma Inc. |
Anti-cd40 antibodies and uses thereof
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
CN113583131B
(zh)
|
2014-08-19 |
2024-09-03 |
默沙东有限责任公司 |
抗tigit抗体
|
|
DK3186283T3
(da)
*
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
CN107074952B
(zh)
|
2014-09-30 |
2021-04-09 |
英特维特国际股份有限公司 |
结合犬pd-l1的pd-l1抗体
|
|
WO2016054638A1
(en)
|
2014-10-03 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
|
WO2016057488A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
|
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗－ｏｘ４０抗體及其用途
|
|
EP3204417B1
(en)
|
2014-10-10 |
2020-07-22 |
Innate Pharma |
Cd73 blockade
|
|
EA201790834A1
(ru)
|
2014-10-14 |
2018-01-31 |
Новартис Аг |
Молекулы антител к pd-l1 и их применение
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
|
AU2015340056A1
(en)
|
2014-10-27 |
2017-05-25 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
SI3215532T1
(sl)
|
2014-11-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Protitelesa proti TIM3 in postopki uporabe
|
|
EP3215538A4
(en)
|
2014-11-07 |
2018-07-04 |
Igenica Biotherapeutics, Inc. |
Anti-cd39 antibodies and uses thereof
|
|
JP6755866B2
(ja)
|
2014-11-10 |
2020-09-16 |
メディミューン リミテッド |
Ｃｄ７３特異的結合分子及びその使用
|
|
US10822414B2
(en)
|
2014-11-11 |
2020-11-03 |
Sutro Biopharma, Inc. |
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
|
|
JP6847037B2
(ja)
|
2014-11-11 |
2021-03-24 |
メディミューン リミテッド |
抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
|
|
HRP20201928T1
(hr)
|
2014-11-20 |
2021-02-05 |
F. Hoffmann - La Roche Ag |
Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
|
|
ES2807182T3
(es)
|
2014-11-21 |
2021-02-22 |
Bristol Myers Squibb Co |
Anticuerpos frente a CD73 y sus usos
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
BR112017013111A2
(pt)
|
2014-12-22 |
2018-05-15 |
Five Prime Therapeutics Inc |
métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
|
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
LT3242685T
(lt)
|
2015-01-09 |
2022-08-25 |
Adalta Limited |
Cxcr4 surišančios molekulės
|
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
CN120988137A
(zh)
|
2015-01-23 |
2025-11-21 |
赛诺菲 |
抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
EP3253413A2
(en)
|
2015-02-06 |
2017-12-13 |
Kadmon Corporation, LLC |
Immunomodulatory agents
|
|
EP4151231A1
(en)
|
2015-02-13 |
2023-03-22 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
|
EP3259288A1
(en)
|
2015-02-20 |
2017-12-27 |
Innate Pharma |
Cd73 blockade
|
|
CN107921104A
(zh)
|
2015-02-22 |
2018-04-17 |
索伦托治疗有限公司 |
结合cd137的抗体疗法
|
|
KR20250005465A
(ko)
|
2015-03-03 |
2025-01-09 |
키맵 리미티드 |
항체, 용도 및 방법
|
|
US9434785B1
(en)
|
2015-04-30 |
2016-09-06 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
|
US9512229B2
(en)
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
IL292449B2
(en)
|
2015-03-13 |
2024-02-01 |
Cytomx Therapeutics Inc |
Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
|
|
TWI719970B
(zh)
|
2015-03-23 |
2021-03-01 |
美商永斯醫療股份有限公司 |
針對ｉｃｏｓ之抗體
|
|
US10836827B2
(en)
|
2015-03-30 |
2020-11-17 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
FI3277321T3
(fi)
|
2015-04-01 |
2024-10-31 |
Anaptysbio Inc |
T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
|
|
US10273305B2
(en)
|
2015-04-02 |
2019-04-30 |
Ablynx N.V. |
Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
|
|
JP6971850B2
(ja)
|
2015-04-13 |
2021-11-24 |
ファイヴ プライム セラピューティクス インク |
がんの併用療法
|
|
US20180298095A1
(en)
|
2015-04-24 |
2018-10-18 |
The Brigham And Women's Hospital, Inc. |
Interactions between ceacam and tim family members
|
|
JP2018521959A
(ja)
|
2015-04-29 |
2018-08-09 |
サンフォード−バーナム メディカル リサーチ インスティテュート |
Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション
|
|
WO2016178779A1
(en)
|
2015-05-01 |
2016-11-10 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti ccr4 antibodies
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
TWI716405B
(zh)
|
2015-05-07 |
2021-01-21 |
美商艾吉納斯公司 |
抗ox40抗體及其使用方法
|
|
EP3091032A1
(en)
|
2015-05-08 |
2016-11-09 |
Miltenyi Biotec GmbH |
Humanized antibody or fragment thereof specific for cd3
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
CN107810198B
(zh)
|
2015-05-29 |
2021-09-03 |
艾伯维公司 |
抗cd40抗体及其用途
|
|
HRP20201031T1
(hr)
|
2015-05-29 |
2020-10-16 |
Agenus Inc. |
Anti-ctla-4 protutijela i postupci njihove upotrebe
|
|
MA44699A
(fr)
|
2015-05-29 |
2021-05-05 |
Merck Sharp & Dohme |
Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
|
|
RS63897B1
(sr)
|
2015-05-29 |
2023-02-28 |
Bristol Myers Squibb Co |
Antitela protiv ox40 i njihova primena
|
|
ES2810856T3
(es)
|
2015-06-03 |
2021-03-09 |
Bristol Myers Squibb Co |
Anticuerpos ANTI-GITR para diagnóstico de cáncer
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
TWI870335B
(zh)
|
2015-06-12 |
2025-01-21 |
美商宏觀基因股份有限公司 |
變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
|
|
WO2016205042A1
(en)
|
2015-06-16 |
2016-12-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRPα AGONIST ANTIBODY
|
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体及び使用方法
|
|
CR20170537A
(es)
|
2015-06-24 |
2018-02-20 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias.
|
|
CN114805576A
(zh)
|
2015-06-24 |
2022-07-29 |
詹森药业有限公司 |
抗vista抗体和片段
|
|
AU2016285913B2
(en)
|
2015-06-29 |
2022-06-16 |
Bristol-Myers Squibb Company |
Antibodies to CD40
|
|
CA2990015A1
(en)
|
2015-06-29 |
2017-01-05 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
|
CN106331470A
(zh)
|
2015-07-03 |
2017-01-11 |
中兴通讯股份有限公司 |
一种拍摄终端和拍摄方法
|
|
JP7010811B2
(ja)
|
2015-07-10 |
2022-02-10 |
メルス ナムローゼ フェンノートシャップ |
ヒトｃｄ３結合抗体
|
|
BR112018000696A2
(pt)
|
2015-07-15 |
2018-09-18 |
Genmab As |
?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
|
|
CN114853891A
(zh)
|
2015-07-22 |
2022-08-05 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
ES2898958T3
(es)
|
2015-07-30 |
2022-03-09 |
Macrogenics Inc |
Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
WO2017021910A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
US11008391B2
(en)
|
2015-08-11 |
2021-05-18 |
WuXi Biologics Ireland Limited |
Anti-PD-1 antibodies
|
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
|
CN108290936B
(zh)
|
2015-08-14 |
2022-07-12 |
默沙东公司 |
抗tigit抗体
|
|
WO2017031242A1
(en)
|
2015-08-20 |
2017-02-23 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
HUE063528T2
(hu)
|
2015-09-01 |
2024-01-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére
|
|
HK1257840A1
(zh)
|
2015-09-01 |
2019-11-01 |
Agenus Inc. |
抗-pd-1抗体及其使用方法
|
|
RU2021133819A
(ru)
|
2015-09-02 |
2021-12-10 |
Иммутеп С.A.С. |
Анти-lag-3 антитела
|
|
US10946095B2
(en)
|
2015-09-02 |
2021-03-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
|
|
EP3307322B1
(en)
|
2015-09-04 |
2021-02-17 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
|
WO2017049038A2
(en)
|
2015-09-16 |
2017-03-23 |
Ablexis, Llc |
Anti-cd115 antibodies
|
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ｏｘ４０抗体及びその診断用途
|
|
IL288784B2
(en)
|
2015-09-24 |
2023-10-01 |
Daiichi Sankyo Co Ltd |
Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
|
|
CR20220186A
(es)
|
2015-09-25 |
2022-07-07 |
Genentech Inc |
ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225)
|
|
CN108289953B
(zh)
|
2015-09-29 |
2022-03-11 |
细胞基因公司 |
Pd-1结合蛋白及其使用方法
|
|
BR112018006547A2
(pt)
|
2015-09-29 |
2018-12-11 |
Asia Biotech Pte. Ltd |
anticorpos de pd-1 e usos dos mesmos
|
|
JP2018529351A
(ja)
|
2015-09-30 |
2018-10-11 |
ヤンセン バイオテツク，インコーポレーテツド |
ヒトｃｄ４０に特異的に結合するアンタゴニスト抗体及び使用方法
|
|
AU2016331052B2
(en)
|
2015-10-01 |
2023-08-03 |
Potenza Therapeutics, Inc. |
Anti-TIGIT antigen-binding proteins and methods of use thereof
|
|
IL257110B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Bispecific antibodies specific against pd1 and tim3
|
|
IL258214B2
(en)
|
2015-10-02 |
2023-04-01 |
Symphogen As |
Antibodies - anti pd-1 and preparations
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
|
CN114380908B
(zh)
|
2015-10-15 |
2023-03-17 |
苏州丁孚靶点生物技术有限公司 |
抗ox40抗体及其应用
|
|
CA2998208A1
(en)
|
2015-10-22 |
2017-04-27 |
Jounce Therapeutics, Inc. |
Gene signatures for determining icos expression
|
|
CN106632674B
(zh)
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
|
GB201519481D0
(en)
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
|
WO2017087547A1
(en)
|
2015-11-17 |
2017-05-26 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
|
GEP20207174B
(en)
|
2015-11-18 |
2020-11-10 |
Merck Sharp & Dohme |
Ctla4 binders
|
|
SG10201911035QA
(en)
|
2015-11-18 |
2020-01-30 |
Merck Sharp & Dohme |
Pd1 and/or lag3 binders
|
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技（上海）有限公司 |
抗pd-1抗体及其治疗用途
|
|
WO2017087587A1
(en)
|
2015-11-18 |
2017-05-26 |
Merck Sharp & Dohme Corp. |
PD1/CTLA4 Binders
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
|
EP3383904A4
(en)
|
2015-11-19 |
2019-12-04 |
Zeling Cai |
CTLA-4 ANTIBODIES AND USES THEREOF
|
|
US20190153113A1
(en)
|
2015-11-23 |
2019-05-23 |
Innate Pharma |
Cd39 vascular isoform targeting agents
|
|
US20180291107A1
(en)
|
2015-11-24 |
2018-10-11 |
Eli Lilly And Company |
Combination therapy for cancer
|
|
CN106939047B
(zh)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
|
BR112018015480A2
(pt)
|
2016-01-29 |
2019-05-21 |
Sorrento Therapeutics, Inc. |
proteínas de ligação ao antígeno que se ligam a pd-l1
|
|
US10465014B2
(en)
|
2016-03-04 |
2019-11-05 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
|
|
PT3455257T
(pt)
|
2016-05-09 |
2021-12-06 |
Igm Biosciences Inc |
Anticorpos anti-pd-l1
|
|
CN105968200B
(zh)
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
|
WO2017213695A1
(en)
|
2016-06-07 |
2017-12-14 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
|
|
AU2017284632B2
(en)
|
2016-06-13 |
2020-05-14 |
I-Mab Biopharma Co., Ltd. |
Anti-PD-L1 antibodies and uses thereof
|
|
US10077308B2
(en)
|
2016-06-13 |
2018-09-18 |
Askgene Pharma Inc. |
PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
|
|
CN116903741A
(zh)
|
2016-06-20 |
2023-10-20 |
科马布有限公司 |
特异性结合于pd-l1的抗体或其抗原结合片段及其用途
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
SI3472207T1
(sl)
|
2016-06-20 |
2021-04-30 |
F-Star Delta Limited |
Vezavne molekule, ki vežejo PD-L1 in LAG-3
|
|
CA3027204A1
(en)
|
2016-06-29 |
2018-01-04 |
Checkpoint Therapeutics, Inc. |
Pd-l1-specific antibodies and methods of using the same
|
|
ES3000676T3
(en)
|
2016-07-07 |
2025-03-03 |
Iovance Biotherapeutics Inc |
Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
|
|
AU2017305366B2
(en)
|
2016-08-04 |
2019-06-20 |
Innovent Biologics (Suzhou) Co., Ltd |
Anti-PD-L1 nanobody and use thereof
|
|
US11649289B2
(en)
|
2016-08-04 |
2023-05-16 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-ICOS and anti-PD-1 antibody combination therapy
|
|
US10919966B2
(en)
|
2016-08-05 |
2021-02-16 |
Y-Biologics Inc. |
Antibody to programmed death-ligand 1 (PD-L1) and use thereof
|
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
IL300982B2
(en)
|
2016-09-10 |
2024-08-01 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity fortreatment of " disease and injury of the cns
|
|
IL265485B2
(en)
|
2016-09-20 |
2024-07-01 |
Pfizer |
Diagnostic anti-PD-L1 antibody and its use
|
|
KR102543323B1
(ko)
|
2016-10-30 |
2023-06-14 |
상하이 헨리우스 바이오테크, 인크. |
항-pd-l1 항체 및 변이체
|
|
SI3535298T1
(sl)
|
2016-11-02 |
2022-01-31 |
Jounce Therapeutics, Inc. |
Protitelesa proti pd-1 in njihove uporabe
|
|
WO2018115859A1
(en)
|
2016-12-20 |
2018-06-28 |
Kymab Limited |
Multispecific antibody with combination therapy for immuno-oncology
|
|
EP3559045A4
(en)
|
2016-12-23 |
2020-08-19 |
REMD Biotherapeutics, Inc. |
IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
|
|
WO2018136553A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
|
LT3592769T
(lt)
|
2017-03-09 |
2024-08-26 |
Genmab A/S |
Antikūnai, atpažįstantys pd-l1
|
|
US20200024351A1
(en)
|
2017-04-03 |
2020-01-23 |
Jounce Therapeutics, Inc. |
Compositions and Methods for the Treatment of Cancer
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
EP3612565A4
(en)
|
2017-04-18 |
2021-06-16 |
R-Pharm Overseas, Inc. |
ANTI-PD-L1 ANTIBODIES AND ITS USE
|
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
US11492384B2
(en)
*
|
2018-09-17 |
2022-11-08 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|
|
US10442866B1
(en)
|
2019-01-23 |
2019-10-15 |
Beijing Mabworks Biotech Co. Ltd |
Antibodies binding OX40 and uses thereof
|